Soldiers returning from a warzone. Athletes who’ve taken too many blows to the head. Almost anyone who’s been in a car accident. Traumatic brain injury (TBI) is a serious condition that affects millions of individuals each year. In fact, over 2.5 million people suffer some type of traumatic brain injury annually. But while there are some medications currently being used to treat traumatic brain injury, many treatment protocols fall short of repairing the damage completely. With this in mind, Endonovo Therapeutics Inc. is investigating the use of its non-invasive electroceuticals to manage this devastating condition. As a commercial developer of various electromagnetic therapeutics, Endonovo Therapeutics’ electroceuticals provide the means to reduce inflammation and thus improve the outcomes for patients.
That’s right. Saving the brain via electric shock. That’s a bold innovation, indeed.
How Do Electroceuticals Fields Work?
A number of research studies in neuromedicine now highlight the potential benefits of electroceuticals. In fact, electroceuticals are believed to use bioelectrical activity to restore normal electrochemical processes throughout the body. This explains why electroceuticals not only help traumatic brain injury conditions but other disorders as well. The use of Electroceuticals is, therefore, being used or evaluated in wound care, pain, ischemic vascular disease, and kidney disease as a result.
When it comes to traumatic brain injury, the primary benefits of electroceuticals relate to anti-inflammatory effects. Research has shown that electroceuticals suppress the release of inflammatory chemicals after a head injury. In addition, electroceuticals promote nitric oxide production, which improves circulation, protects tissues, and enhances neurotransmission. These findings are what has led Endonovo Therapeutics to begin clinical patient trials in individuals suffering from traumatic brain injury.
Endonovo’s Current Trial Involving Electroceuticals for Traumatic Brain Injury
In terms of the current patient trials, Endonovo enrolled the first traumatic brain injury patient for study in June of this past year. The study is being performed at the University of New Mexico Health Sciences Center, School of Medicine, Department of Neurosurgery. The goal of the research is to enroll 48 participants with traumatic brain injury. Inflammatory chemicals will then be measured as well as neurological outcomes between those receiving electroceuticals treatment and controls. This should provide a better understanding of how significant the benefits of electroceuticals are.
While electroceuticals have the notable potential for reducing the negative effects of traumatic brain injury, other neuromedicine conditions may also benefit. A number of neurological disorders are associated with inflammatory damage that causes deterioration. Some key examples of this include Alzheimer’s, multiple sclerosis, and even stroke. By reducing inflammation and improving nerve cell recovery, electroceuticals could be a treatment for a number of neurologic conditions.
The Expanding Use of Electroceuticals in Healthcare
While the use of electroceuticals brings excitement in neuromedicine, these non-invasive therapies are already useful for other health-related conditions. For example, Endonovo’s SofPulse device uses shortwave, pulsed radiofrequency to reduce pain and swelling. This reduces the need for pain-control drugs and can eliminate opioid use in some cases. In addition, Endonovo’s Roma medical device has been shown to reduce chronic wound size by 70 percent within a week.
Endonovo Therapeutics is also pursuing research and product development in many other healthcare areas as well. For example, electroceuticals are being investigated after heart attacks to promote better blood vessel growth. Studies are also examining what protective effects electroceuticals may have in kidney and liver disease patients. Because electroceuticals reduce inflammation effects, the spectrum of conditions this treatment may help has broad potential.
Endonovo Therapeutics Is Rapidly Growing
Over the next two years, Endonovo Therapeutics anticipates introducing several additional electroceuticals devices. Whether the approval for their use in traumatic brain injury occurs before then remains unclear. But the company has strong funding support and is actively building its sales force and R&D departments for growth. Assuming the present clinical trial align with prior research results, electroceuticals could soon be available for traumatic brain injury management.